Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Atezolizumab bij urotheelcarcinoom
mrt 2017 | Uro-oncologie
nov 2024 | Longoncologie
nov 2024 | Longoncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie
sep 2024